Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single Center, Open Label, Single Dose, Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

NCT05504395 is registered in ClinicalTrials.gov with ConSynance Therapeutics as lead sponsor.

NCT NCT05504395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05504395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single Center, Open Label, Single Dose, Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome
Lead sponsor
ConSynance Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 14, 2022
Completion date
February 21, 2023
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prader-willi syndrome